HealthcareMachine Learning4 min reading time

Brainomix E-Lung Analysis Detects Treatment Effects in Phase 2a IPF Trial

Unite.AI
Read full post
Brainomix and Endeavor BioMedicines reported that Brainomix's AI-powered e-Lung tool detected significant treatment effects of taladegib in a Phase 2a idiopathic pulmonary fibrosis trial by analyzing CT scans. The AI analysis revealed improvements in lung volume, fibrosis extent, and disease burden, supporting its use for sensitive, objective endpoints in clinical trials.

More in Healthcare

UK Is Urged to Overhaul Regulation of AI-Medical Devices

Covered by 2 sources
Healthcare5 min read

​Digital Finance Needs A New Kind Of Identity For AI-Driven Economies

Forbes

How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules

Open AI News